This article was published free of charge. Only PREMIUM Articles are (Google AdSense™) 3rd party Ads-Free!
AspirinWorks Urine Tests for Heart Disease Sufferers Comes to Israel
NewswireToday - /newswire/ -
Hod Hasharon, Sharon, Israel, 11/24/2009 - Corgenix’s AspirinWorks urine tests for heart disease sufferers is being marketed in Israel by the Medison Group. Patients with heart problems now have more effective and simple tests to determine if aspirin treatment will help them.
Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, has signed an exclusive agreement with the Medison Group to market its AspirinWorks test kits in Israel. This will allow individuals with risk of heart attack to rapidly determine if aspirin therapy is effective for them.
The AspirinWorks® Test Kit is an enzyme-linked immunoassay (ELISA) to determine levels of 11-Dehydro Thromboxane B2 (11dhTxB2) in human urine, which aids in the qualitative detection of aspirin effect in apparently healthy individuals post ingestion.
Its strong advantage is its ease of application. Unlike other platelet aggregation tests, which require freshly drawn blood that must be evaluated within 4 hours, AspirinWorks is non-invasive and requires only a urine sample that can easily be obtained in any doctor’s office. It is not time-sensitive.
“Research has shown that up to 25 percent of individuals may be non-responsive to aspirin’s benefits, and are more than three times more likely to die from heart disease,” said Corgenix Clinical Affairs Director Gordon Ens. “This test can tell us if the aspirin fails to elicit an effect, thereby allowing physicians to individualize their patient’s therapy.”
The AspirinWorks® (aspirinworks.com) diagnostic test kit targets a potential U.S. market of over 60 million individuals and a potential global market exceeding 200 million individuals.
More than one million Americans experience new or recurrent heart attacks each year.
About Corgenix Medical Corporation
Corgenix Medical Corporation (OTC BB: CONX) is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products (corgenix.com) are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in advancing products through the FDA process.
About Medison Pharma
Medison Pharma (medisonpharma.com) is a leading Israeli marketing group focused in the fields of high quality pharmaceutical, medical devices and diagnostics products. With over a decade of experience, Medison is uniquely placed to provide a complete A to Z spectrum of integrated services for international companies looking to enter or expand their presence in the Israeli healthcare market, as well as in Romania and Slovakia.
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements
Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!
Distribution: [+] Free Press Release & Newswire Distribution Network. via PRZOOM - Newswire Today (NewswireToday.com)
# # #
Your Banner Ad showing on ALL Pharma/BioTech/Nutrition articles, CATCH Visitors via Your Competitors Announcements! Non-featured company website links are shown on a random basis
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
Contact: Mike Druttman - Futureweb.ws
+972-3-9250250 medison[.]medison.co.il
Newswire Today - PRZOOM disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.